Immunoassays for parasitic diseases mainly apply immunological methods to detect antibodies against parasites or antigens excreted by the parasites themselves in the blood circulation or body fluids of humans or animals. Most of these methods are sensitive and can detect the presence of antibodies or antigens in trace amounts. Therefore, it can provide a basis for determining suspected parasitic infections and is an important diagnostic aid. And in parasitic disease control work, it can further identify patients, monitor changes in the epidemic and evaluate the effectiveness of control work.
Ace Therapeutics focuses on parasitological research and has established a platform for parasite detection technologies to provide high-quality parasite immunological testing services, including intradermal testing (ID), cercarian huellen reaction (CHR), circum oval precipitin test (COPT), indirect hemagglutination assay (IHA), immunofluorescence technique, enzyme-linked immunosorbent assay (ELISA), colloidal gold labeling technology, etc. We aim to provide assistance for parasite detection and accelerate research for our customers worldwide.
Depending on the type of sample and test method, we offer a wide range of parasite immunology testing services, giving you the flexibility to choose. Of course, the range of services that can be offered includes, but is not limited to:
Cercarian huellen reaction (CHR) used for early detection of schistosomiasis, with high specificity and sensitivity.
Cyclic egg precipitation test (COPT) is a common method for serological detection of schistosomiasis. It should be used for early diagnosis of schistosomiasis and has high specificity and sensitivity.
Indirect hemagglutination assay (IHA) is a serological method that uses red blood cells as the carrier of immune ligand and takes a reading of red blood cell agglutination. It is applied to parasite detection, such as schistosomes, Plasmodium, porcine cysts, trichinella, lung fluke, amoeba, toxoplasma, liver fluke.
Immunofluorescence technique (IFA) is an immunological labeling technique that uses fluorescein-labeled antibodies to detect antigens or antibodies. It is used for the diagnosis of malaria, filariasis, schistosomiasis, pulmonary schistosomiasis, tachistosomiasis, onchocerciasis and toxoplasmosis.
Enzyme-linked immunosorbent assay has been widely used for the detection of specific antibodies or antigenic particles in host fluids (serum, cerebrospinal fluid, etc.) and excretory secretions (urine, milk, feces, etc.) of various parasitic infections.
This technique involves capturing the cytokines secreted by cultured cells with antibodies and expressing them as enzyme-linked spot colour development. ELISPOT can be used not only for direct clinical diagnosis, but also as an important reference for treatment and drug use.
Also known as immunoblotting or Western blot, is used for parasite antigen analysis and immunodiagnosis of parasitic diseases.
For the diagnosis and epidemiological investigation of schistosomiasis, Schistosoma haematobium, schistosomiasis, filariasis, porcine cysticercosis and toxoplasmosis.
For the experimental diagnosis and epidemiological investigation of schistosomiasis, filariasis, and black fever.
Immunodiffusion and immunoelectrophoresis are used for the immunodiagnosis of certain parasitic diseases as well as for the identification of parasitic antigens and the detection of titres of immune sera.
Please let us know the details of your parasite testing related project through online inquiry. We will reply to you promptly and provide you with a feasibility assessment and experimental protocol for your project. After reaching an agreement and getting the samples, we proceed to the testing phase as soon as possible. After the testing is completed, we will deliver a detailed report to you.
Ace Therapeutics is a contract service provider focused on parasitology research, providing innovative solutions and technologies for parasite detection, genetic engineering, and drug development. We support global research institutes, universities, and pharmaceutical companies in advancing their research goals.